Our findings align with recent studies highlighting the importance of CTCs in predicting treatment outcomes,28,29,30 but extend this knowledge by focusing on specific biomarker phenotypes (CK−/PD-L1+/VIM+) and their clinical relevance in advanced lung cancer. This evidence concerns the gene VIM and lung carcinoma.